Stock Analysts

The FDA Approved Fewer Drugs in 2016: Here’s Why

There was a notable dip in FDA novel drug approvals in 2016 with the agency giving its nod to 22 treatments during the year. Compare this to 45 approvals in 2015 and 41 in 2014 and the 2016 numbers look really disappointing. It’s not like a fewer number of applications were submitted in 2016 — as of Dec 9, 2016, 36 new molecular entity (NME) applications were submitted, in line with the average NME filings of 35 over the past decade. […]

Stock Analysts

5 Airline Stocks Set to Fly High in 2017

It’s time for airline investors to buckle up as 2017 may be another strong year. Revenue per available seat mile (RASM) is projected to increase at a steady clip, while imminent investors like Warren Buffett who has spent most of his life decrying airline investing, recommitted to the industry in November. Thanks to several years of restructuring and re-engineering of businesses, the airline industry is way more resilient now. […]

Stock Analysts

Statoil (STO) Increases Interest in Byrding Project to 70%

Statoil ASA STO recently announced that it has concluded its earlier announced transaction with Wintershall Norge. Per the deal, the former has farmed into 25% interest in the Byrding project on the Norwegian Continental Shelf (“NCS”). Post transaction, Statoil’s operated interest in Byrding (PL090B) has increased to 70% from 45%. […]

Stock Analysts

Pilgrim’s Pride (PPC) Closes GNP Acquisition Worth $350M

Pilgrim's Pride Corporation PPC declared that it has concluded the acquisition of the renowned branded chicken products provider in the Upper Midwest – GNP Company – with an all-cash amount of $350 million. The transaction is likely to boost Pilgrim's Pride’s existing product portfolio and operational efficacy in the near term. Over the last one month, Pilgrim's Pride’s stock recorded a return of 1.22% – outperforming the S&P 500 return of 0.87%. […]

Stock Analysts

Helen of Troy (HELE) Stock Gains After Q3 Earnings Beat

Helen of Troy Limited HELE has been posting positive earnings surprises for the past five quarters. The company continued with this trend in third-quarter fiscal 2017 as well. Shares of the company rose 7.7%, following the company’s better-than-expected results in third-quarter fiscal 2016 on Jan 5, 2016. […]

Mergers & Acquisitions

Allergan Enters Parkinson’s Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-In-Class Breakthrough Compounds

Allergan Enters Parkinson’s Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-In-Class Breakthrough Compounds – Marks Allergan’s Entry into Parkinson’s Disease, an Important Adjacency to Company’s Innovative CNS Development Pipeline – – Lead Compound, LTI-291, Represents a Compelling Opportunity for Treatment of Parkinson’s Disease in a Subpopulation with Specific Genetic Mutations – – Option to Acquire LTI Following Completion of Phase 1b Clinical Trial – PR Newswire DUBLIN and CAMBRIDGE, Mass., Jan. […]

Stock Analysts

ManTech (MANT) Secures $87 Million Contract from US Navy

Security software & services provider ManTech International Corporation MANT was recently awarded a prime contract worth $87 million by the Naval Surface Warfare Center Dahlgren Division (NSWCDD). Per the contract, ManTech will offer Test and Evaluation (T&E) support services to NSWCDD for its weapons and combat systems. The contract has a base period of performance of one year, which can be extended by additional four years. […]

Stock Analysts

5 Toxic Stocks to Get Rid Of or Play Short

Correct identification of the overpriced and fairly priced stocks makes investing foolproof. In reality, however, the overpriced stocks and the correctly priced stocks are mixed in such a manner that it becomes very difficult to pick the wheat from the chaff. Pinpointing the bloated toxic stocks on a regular basis and discarding them at the right time is one of the keys of successful investing […]